Can-Fite BioPharma Ltd. (CANF)
Can-Fite BioPharma Statistics
Share Statistics
Can-Fite BioPharma has 6.1M shares outstanding. The number of shares has increased by 62.34% in one year.
| Shares Outstanding | 6.1M |
| Shares Change (YoY) | 62.34% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 1.57% |
| Shares Floating | 5.19M |
| Failed to Deliver (FTD) Shares | 1.77K |
| FTD / Avg. Volume | 0.95% |
Short Selling Information
The latest short interest is 253.96K, so 0.01% of the outstanding shares have been sold short.
| Short Interest | 253.96K |
| Short % of Shares Out | 0.01% |
| Short % of Float | 0.02% |
| Short Ratio (days to cover) | 1.56 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -2.14. Can-Fite BioPharma's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -2.14 |
| PS Ratio | 0.04 |
| Forward PS | 0 |
| PB Ratio | 0.01 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Can-Fite BioPharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.9, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.9 |
| Quick Ratio | 4.9 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -585.36 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $92.88K |
| Profits Per Employee | $-954.25K |
| Employee Count | 8 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -40% in the last 52 weeks. The beta is 0.46, so Can-Fite BioPharma's price volatility has been higher than the market average.
| Beta | 0.46 |
| 52-Week Price Change | -40% |
| 50-Day Moving Average | 1.57 |
| 200-Day Moving Average | 2.1 |
| Relative Strength Index (RSI) | 43.33 |
| Average Volume (20 Days) | 186.22K |
Income Statement
In the last 12 months, Can-Fite BioPharma had revenue of 743K and earned -7.63M in profits. Earnings per share was -1.79.
| Revenue | 743K |
| Gross Profit | 743K |
| Operating Income | -8.2M |
| Net Income | -7.63M |
| EBITDA | -8.18M |
| EBIT | -8.2M |
| Earnings Per Share (EPS) | -1.79 |
Balance Sheet
The company has 4.28M in cash and 40K in debt, giving a net cash position of 4.24M.
| Cash & Cash Equivalents | 4.28M |
| Total Debt | 40K |
| Net Cash | 4.24M |
| Retained Earnings | -158.48M |
| Total Assets | 5.92M |
| Working Capital | 3.84M |
Cash Flow
In the last 12 months, operating cash flow was -8.44M and capital expenditures -2K, giving a free cash flow of -8.44M.
| Operating Cash Flow | -8.44M |
| Capital Expenditures | -2K |
| Free Cash Flow | -8.44M |
| FCF Per Share | -1.98 |
Margins
Gross margin is 100%, with operating and profit margins of -1102.96% and -1027.46%.
| Gross Margin | 100% |
| Operating Margin | -1102.96% |
| Pretax Margin | -1027.46% |
| Profit Margin | -1027.46% |
| EBITDA Margin | -1100.94% |
| EBIT Margin | -1102.96% |
| FCF Margin | -1136.2% |
Dividends & Yields
CANF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CANF is $10, which is 609.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 609.2% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jan 9, 2023. It was a forward split with a ratio of 10:1.
| Last Split Date | Jan 9, 2023 |
| Split Type | forward |
| Split Ratio | 10:1 |
Scores
| Altman Z-Score | -40.44 |
| Piotroski F-Score | 2 |